Trial Profile
Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare a Dry Powder Oral Suspension (10 mg and 20 mg Dose of Rivaroxaban) With an Oral Suspension (10 mg of Rivaroxaban) and 10 mg of an Immediate Release Tablet Under Fasting Conditions (10 mg Doses) and Under Fed Conditions (20 mg Dose) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2015
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Rivaroxaban (Primary)
- Indications Thromboembolism; Thrombosis
- Focus Pharmacokinetics
- Sponsors Bayer
- 09 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 09 Mar 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 24 Feb 2015 New trial record